A new study finds that deep brain stimulation (DBS) is associated with significantly lower mortality, reduced institutionalization, and lower healthcare costs in Parkinson's disease patients. Tracking nearly 80,000 hospitalized PD patients over five years, researchers found DBS recipients were far less likely to die or end up in long-term care. The findings suggest DBS offers durable, real-world benefits beyond symptom control.
A large real-world study published in npj Parkinson's Disease found that deep brain stimulation (DBS) is associated with meaningfully better long-term outcomes for patients with Parkinson's disease (PD) — including lower mortality, reduced institutionalization, and significantly lower healthcare costs.
The retrospective cohort study analyzed nearly 80,000 hospitalized U.S. adults with confirmed PD in 2018, following them for up to five years post-discharge. Of these, 482 patients underwent DBS implantation during hospitalization, while the remaining 79,363 did not. Researchers tracked hospital readmissions, institutionalization, all-cause mortality, and total medical costs at 1, 3, and 5 years.
By the Numbers:
Why it matters: These findings suggest DBS isn't just a symptom-management tool — it may offer a durable survival advantage and reduce the long-term financial burden of Parkinson's care, making equitable access to DBS an increasingly important clinical priority.
